Novavax says its vaccine is 89% effective against Corona

Novavax said, yesterday, Thursday, that an initial analysis showed that its vaccine against the Corona virus is 89.3% effective in preventing Covid-19 disease in an experiment conducted in Britain, and it provides almost the same level of protection from the most contagious strain that was first discovered there. .

And a vaccine trial in South Africa, where a disturbing new type of virus is spreading, showed 60% effectiveness among people who had not been infected with the HIV virus that causes AIDS.

Novavax shares jumped by 34% in after-hours trading, following the announcement of the test results, on the same day that the United States recorded its first case of the South African strain.

Novavax already stores the vaccine at six manufacturing sites, and said it expects a total of eight factories in seven countries to produce an average of two billion doses per year, including doses from the Indian Serum Institute for Serum and Vaccine.

The company said in a conference call that these are interim data, and its top officials have expected two to three months to pass before they are ready to apply for a license from regulators.

The British experiment was conducted on 15 thousand people between the ages of 18 and 84 years, and it is expected that they will be used to apply for the use of the vaccine in Britain, the European Union and others.

Approval of the Novavax vaccine will be most welcome in Europe, which is struggling to obtain other supplies of vaccines after it received less than hoped quantities of the Pfizer / Biontech and AstraZeneca vaccines.

Follow our latest local and sports news, and the latest political and economic developments via Google news